Prostate cancer remains a frequently diagnosed condition among men globally, particularly impacting older populations [2]. While initial treatments often successfully manage localized forms of the disease, recurrent or advanced stages present unique clinical challenges. When the disease progresses despite initial interventions, comprehensive management becomes essential for extending life and preserving overall well-being [2].
The Role of Hormone Therapy and Resistance
Androgen deprivation therapy has historically served as the foundation of treatment for recurrent or metastatic prostate cancer [2]. Because prostate cancer growth is frequently fueled by male hormones, lowering these hormone levels helps control the disease. Unfortunately, nearly all patients eventually develop resistance to standard androgen blockade, transitioning into a phase known as metastatic castration-resistant prostate cancer [2]. This development requires a shift toward more advanced therapeutic strategies designed to target alternative survival pathways utilized by the cancer cells.
Expanding Systemic Treatment Options
Over the past decade, clinical advancements have significantly improved survival outcomes for men facing advanced disease stages [2]. Current systemic management protocols incorporate a variety of potent medical approaches. These include androgen receptor-axis inhibitors, specialized taxane-based chemotherapies such as docetaxel and cabazitaxel, radiopharmaceuticals, and immunotherapeutic agents like Sipuleucel-T [2, 5]. Furthermore, combining chemotherapy with primary hormonal therapy has been established as a standard care approach for high-volume castration-sensitive metastatic disease to optimize initial control [5].
Targeted Radiopharmaceutical Therapy and Safety
Radiopharmaceutical therapy represents an established treatment modality for patients with advanced metastatic castration-resistant prostate cancer [3]. Specifically, treatments like 177Lu-PSMA-617 deliver targeted radiation directly to cancer cells expressing prostate-specific membrane antigen. Because the radiotracer clears through the urinary system, the kidneys experience measurable radiation exposure [3]. Consequently, clinical management protocols require rigorous, routine monitoring of renal function markers—such as serum creatinine and estimated glomerular filtration rate—before each treatment cycle and during post-therapy follow-ups to ensure patient safety, particularly in individuals with pre-existing renal impairments or comorbidities [3].
Addressing Emotional Health and Psychological Support
Beyond physical treatments, comprehensive patient management must address the psychological burden associated with advanced cancer diagnoses. Research indicates that patients face significant rates of clinical depression and anxiety throughout their medical journey [1]. Studies evaluating psychological prevalence find that anxiety and depression fluctuate across treatment stages, with notable percentages of patients experiencing distress before, during, and after therapy [1]. Integrating mental health screening and supportive counseling into routine oncology care is therefore vital for addressing the holistic needs of patients and their families.
Conclusion
Managing advanced prostate cancer requires a multidisciplinary framework that balances aggressive life-prolonging therapies with vigilant monitoring of organ function and mental health. As therapeutic options continue to evolve, personalized treatment plans help clinicians navigate drug resistance, minimize adverse effects, and support overall quality of life.
Sources
- [1] Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. PubMed
- [2] Advancing therapies in metastatic castration-resistant prostate cancer. PubMed
- [3] Renal Function During and After <sup>177</sup>Lu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer. PubMed
- [5] Chemotherapy in Prostate Cancer. PubMed